Brieflands
Journal finderSearch
·
Sign in

Iranian Journal of Pharmaceutical Research

e-ISSN 1726-6890
p-ISSN 1735-0328
Home
Archives
    Current IssueAll IssuesIn PressAccepted Manuscripts
Search
Instructions
About Journal
    Journal InformationEditors & BoardsIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormSupportContact Us
APC
Authors GuideSubmit manuscript
  1. Brieflands
  2. /
  3. journals
  4. /
  5. Iranian Journal of Pharmaceutical Research
  6. /
  7. Articles
  8. /
  9. Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention
  10. /
  11. Scopus by Title (Ref)
Citation data

Scopus by Title (Ref)

Articles that cite the referenced work, matched by title from the Scopus database.

5 results·Updated October 11, 2026
← Back to article
1

Ticagrelor plus aspirin vs clopidogrel plus aspirin in mild non-cardioembolic ischemic stroke: A randomized, controlled, active comparator arm, outcome assessor blind, feasibility study

Neurology Asia

2026

Tabrizi N.

2

Aspirin and clopidogrel resistance; a neglected gap in stroke and cardiovascular practice in Iran: a systematic review and meta-analysis

Thrombosis Journal

December 2023

Parsa-kondelaji M.

Open Access

3

The impact of clopidogrel resistance on clinical outcome of Iranian patients undergoing percutaneous coronary intervention

Iranian Journal of Pharmaceutical Research

Summer 2018

Aghajani M.H.

4

Clopidogrel resistance in peripheral arterial disease: Literature survey

Tijdschrift Voor Geneeskunde

2016

Janssens K.

5

Variations in intraplatelet phospho-VASP expression due to pre-analytical sample preparations, illustration of a quality control issue in platelet pharmacology

Iranian Journal of Pharmaceutical Research

1 December 2015

Gharehbaghian A.

Need help?

Editorial, submission and technical questions all go to the same desk.

Submit a ticket
Brieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.